Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
LONG-TERM RISPERIDONE TREATMENT IN BIPOLAR DISORDER - 6-MONTH FOLLOW-UP
Autore:
GHAEMI SN; SACHS GS;
Indirizzi:
GEORGE WASHINGTON UNIV,DEPT PSYCHIAT,BIPOLAR DISORDER RES PROGRAM,2150 PENN AVE NW,8TH FLOOR WASHINGTON DC 20037 MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,BIPOLAR RES PROGRAM BOSTON MA 02114 HARVARD UNIV,SCH MED,CONSOLIDATED DEPT PSYCHIAT BOSTON MA 00000
Titolo Testata:
International clinical psychopharmacology
fascicolo: 6, volume: 12, anno: 1997,
pagine: 333 - 338
SICI:
0268-1315(1997)12:6<333:LRTIBD>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
SCHIZOAFFECTIVE DISORDER; MANIA; SCHIZOPHRENIA; PREDICTORS; ILLNESS;
Keywords:
BIPOLAR DISORDER; RISPERIDONE; MANIC DEPRESSIVE ILLNESS; TREATMENT RESISTANCE;
Tipo documento:
Article
Natura:
Periodico
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
S.N. Ghaemi e G.S. Sachs, "LONG-TERM RISPERIDONE TREATMENT IN BIPOLAR DISORDER - 6-MONTH FOLLOW-UP", International clinical psychopharmacology, 12(6), 1997, pp. 333-338

Abstract

Antipsychotic agents, such as clozapine and risperidone, have been reported to be beneficial in the treatment of some bipolar patients. Many bipolar patients experience `breakthrough episodes' of mood disorder, with mania or depression recurring despite adequate ongoing levels of one or more mood-stabilizing medications. There are no controlled studies of breakthrough episodes, and there is little open experience toguide clinicians in pharmacotherapy of breakthrough episodes. This report describes the outcome of adjunctive risperidone treatment in breakthrough episodes of bipolar disorder. We assessed the outcome of openly adding risperidone to the medication regimen of 12 outpatients withbipolar disorder, type I, who suffered breakthrough episodes despite adequate maintenance medication (lithium, valproate, or carbamazepine,or a combination of these). Prospective ratings were made at each clinical visit using the Clinical Global Impressions and Global Assessment of Functioning scales. Patients received risperidone for a mean of 6.0 months (23.96 weeks, range 0.5-72 weeks) at a mean dose of 2.75 mg/day (range 1-4.5 mg/day). Four patients discontinued medication (two because of lack of efficacy at weeks 6 and 64, and two because of adverse events at weeks 0.5 and 23). Among the remaining eight patients, four experienced a 10-25 point improvement in Global Assessment of Functioning scores and were rated much better on the Clinical Global Impression-Improvement scale. Although one patient suffered a major depressive recurrence (at week 22), no patient experienced worsening of mania. This small open series suggests a subgroup of bipolar patients with breakthrough episodes may benefit from treatment with risperidone.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 09:00:16